COVID-19 Research Paper Volume 13, Issue 6 pp 7758—7766
Convalescent plasma to treat COVID-19: clinical experience and efficacy
- 1 Hunan Engineering Research Center of Obstetrics and Gynecological Disease, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
- 2 Department of Dermatology, Hunan Engineering Research Center of Skin Heath and Disease, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
- 3 Department of Blood Transfusion of Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
- 4 Department of Blood Transfusion Laboratory of Changsha Blood Center, Changsha 410008, Hunan Province, China
* Equal contribution
Received: April 16, 2020 Accepted: December 18, 2020 Published: March 18, 2021
https://doi.org/10.18632/aging.202795How to Cite
Copyright: © 2021 Pei et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
The recent outbreak of COVID-19 in the world is currently a big threat to global health and economy. Convalescent plasma has been confirmed effective against the novel corona virus in preliminary studies. In this paper, we first described the therapeutic schedule, antibody detection method, indications, contraindications of the convalescent plasmas and reported the effectiveness of convalescent plasma therapy by a retrospective cohort study.